Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.

Official Title

A Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, International, Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Histologically-proven primary hepatocellular carcinoma with curative resection performed in the 4 - 6 weeks prior to randomisation. - ECOG performance status 0 to 2 - Child Pugh classification A or B Key
Exclusion Criteria:
  1. - Any evidence of tumour metastasis or co-existing malignant disease - Any prior recurrence of HCC or any liver resection prior to the most recent procedure - History of prior HCC therapy


Samuel So, MD
Samuel So, MD
Surgical oncologist, Liver surgeon, General surgeon
Lui Hac Minh Professor in the School of Medicine

Contact us to find out if this trial is right for you.


Kerry Hsieh